Loading...
Market
How will Abbott's stock price change within one week after the Similac trial outcome?
2
Resolution / Starting Odds
Increase by more than 5% • 25%
Decrease by more than 5% • 25%
Change less than 5% • 25%
No significant change • 25%
Stock market data from reputable financial sources
Story
Abbott Faces Trial on July 8 Over Claims Similac Preterm Infant Formula Causes Dangerous Disease
Jul 8, 2024, 10:11 AM
Abbott, the maker of Similac baby formula, is set to face a trial on Monday, July 8, over allegations that its specialty formula for preterm infants causes a serious intestinal disease. This trial marks the second in a series of hundreds of similar lawsuits in the United States. The formula is used in neonatal intensive care units and is accused of causing a potentially deadly bowel disease. The case has seen nutrition companies and parents clash in court over the cause of the disease.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Verdict upheld • 25%
Verdict overturned • 25%
Settlement reached • 25%
Other • 25%
Stock price increases by over 10% • 25%
Stock price decreases by over 10% • 25%
Stock price remains within 10% range • 25%
Stock is delisted • 25%
Yes • 50%
No • 50%
Significant loss • 25%
Moderate loss • 25%
No significant impact • 25%
Positive impact • 25%
Increase by more than 10% • 25%
Increase by up to 10% • 25%
Decrease by up to 10% • 25%
Decrease by more than 10% • 25%
Yes • 50%
No • 50%
Increase by more than 5% • 25%
Increase by 0-5% • 25%
Decrease by 0-5% • 25%
Decrease by more than 5% • 25%
Increases by more than 5% • 25%
Decreases by more than 5% • 25%
Changes by less than 5% • 25%
No significant change • 25%
Increase by more than 20% • 25%
Increase by 10% to 20% • 25%
Increase by less than 10% • 25%
Decrease • 25%